By Billy Candra 
A groundbreaking new study suggests that tailoring breast cancer screening to a woman’s individual risk profile may be significantly safer and more effective than adhering to a one-size-fits-all approach of routine annual mammograms for everyone. By aligning screening frequency and modality with personal risk levels, researchers discovered it was possible to reduce the incidence of advanced cancer diagnoses while simultaneously ensuring that individuals received the appropriate level of screening necessary for their specific risk, marking a potential paradigm shift in breast cancer prevention and early detection.
This transformative finding emerges from the initial phase of the WISDOM study, which gathered data from 46,000 women across the United States. The results, coordinated by UCSF, advocate for a fundamental re-evaluation of how breast cancer screening is approached, moving away from rigid age-based directives and towards a more nuanced system founded on comprehensive individual risk evaluation. Published on December 12 in JAMA and concurrently presented at the prestigious San Antonio Breast Cancer Symposium, this research introduces a robust framework for personalized breast health management.
The Limitations of Age-Based Screening: A Historical Perspective
For decades, breast cancer screening guidelines have largely operated under the assumption that most women face a similar baseline risk, with age serving as the primary determinant for when to begin and how often to screen. This approach, while well-intentioned and instrumental in reducing breast cancer mortality, has long been subject to debate and scrutiny among medical professionals and public health experts.
Historically, the widespread adoption of mammography in the latter half of the 20th century revolutionized breast cancer detection. Before its advent, many cancers were only discovered at later, more advanced stages, leading to poorer prognoses. National screening programs, championed by organizations like the American Cancer Society (ACS), recommended annual mammograms for women starting at age 40 or 50, aiming to catch cancers early when they are most treatable. These guidelines, while effective at a population level, have always grappled with balancing the benefits of early detection against potential harms such as overdiagnosis, overtreatment, false positives, and the psychological burden associated with follow-up procedures.
Current guidelines from various prominent organizations illustrate the existing disparities and the lack of consensus. For instance, the ACS recommends annual mammograms for women aged 40-44 if they choose, and annually for women 45-54, then every two years for women 55 and older. In contrast, the U.S. Preventive Services Task Force (USPSTF) recommends biennial screening for women aged 40-74. The American College of Obstetricians and Gynecologists (ACOG) suggests annual or biennial screening for women aged 40-74. These variations underscore the complexity of universal recommendations and highlight the inherent limitations of relying solely on age as a risk factor, especially when research has consistently demonstrated that breast cancer risk can vary dramatically from one individual to another, influenced by a myriad of genetic, biological, and lifestyle factors.
"These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," asserted Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author. Dr. Esserman emphasized, "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies."
Breast cancer remains an immense public health challenge, standing as the most commonly diagnosed cancer among women in the United States, excluding skin cancers. According to the National Cancer Institute, approximately 1 in 8 women will be diagnosed with breast cancer in their lifetime. In 2023, an estimated 297,790 new cases of invasive breast cancer and 55,720 cases of non-invasive (in situ) breast cancer were expected to be diagnosed in women in the U.S., with approximately 43,170 women projected to die from the disease. These stark figures underscore the urgent need for more precise and effective screening strategies.
The WISDOM Study: Unpacking the Personalized Approach
The WISDOM study directly compared the long-established practice of traditional annual mammography with a novel screening strategy rooted in individual risk assessment. Utilizing well-validated risk models, researchers meticulously categorized participants into four distinct groups based on a comprehensive evaluation of factors including age, genetic information, lifestyle choices, personal health history, and breast density – a crucial element often overlooked in standard screening protocols.
The detailed stratification provided clear, tailored recommendations:
- Lowest Risk Group (26% of participants): Women in this category were advised to delay routine screening until age 50 or until an advanced algorithm indicated their individual risk had naturally elevated to that of a typical 50-year-old woman. This approach aims to reduce unnecessary screenings, potential anxiety from false positives, and cumulative radiation exposure for those at genuinely low risk.
- Average Risk Group (approximately 62% of participants): For this majority cohort, screening every two years was recommended. This frequency aligns with some existing guidelines for average-risk women and seeks to optimize detection while minimizing over-screening.
- Elevated Risk Group (8% of participants): Individuals in this category were advised to undergo annual mammograms, recognizing their heightened susceptibility to the disease.
- Highest Risk Group (2% of participants): This group, representing the most vulnerable, received the most intensive screening protocol: twice-yearly screening, alternating between mammography and MRI, irrespective of age. This aggressive strategy ensures maximum vigilance for women with profoundly elevated risk factors, allowing for the earliest possible detection of potentially aggressive cancers.
Crucially, the study demonstrated that this personalized screening approach did not result in a higher rate of late-stage cancer diagnoses, effectively debunking concerns that less frequent screening for lower-risk groups might lead to missed cancers. Furthermore, the high acceptance rate of the personalized approach among participants was notable; among those who chose not to be randomized and instead joined an observational group, a significant 89% opted for the risk-based screening strategy, indicating strong patient confidence and preference for tailored care.
"Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," noted co-author Jeffrey A. Tice, MD, a UCSF professor of Medicine specializing in the development and evaluation of breast cancer risk assessment tools. This sentiment highlights the study’s potential to not only improve patient outcomes but also optimize healthcare resource allocation, making screening programs more sustainable and impactful.
Personalized Prevention for Higher-Risk Women: Beyond Detection
The WISDOM study’s innovative framework extended beyond mere screening recommendations to encompass personalized prevention strategies, particularly for participants identified as having elevated or highest risk. This holistic approach recognized that early detection is just one facet of comprehensive cancer management.
High-risk participants received customized guidance aimed at actively lowering their chances of developing breast cancer. This support system included invaluable access to an intuitive online decision-making tool specifically focused on breast health, alongside direct contact with a dedicated breast health specialist. These specialists provided tailored recommendations covering modifiable lifestyle changes, such as adopting a healthier diet and increasing physical activity – interventions known to significantly impact cancer risk. Moreover, discussions included the potential benefits and risks of medications that can help reduce breast cancer risk, such as selective estrogen receptor modulators (SERMs) or aromatase inhibitors, where appropriate. This proactive engagement empowers women to take an active role in their long-term health and risk mitigation.
Expanding Genetic Testing: Uncovering Hidden Risks
Since its inception in 2016, the WISDOM study has expanded its reach, enrolling over 80,000 women to date. A more recent phase has included women as young as 30, driven by the critical need to identify those who may face an increased risk of aggressive early-onset cancers due to inherited genetic variants.
One of the study’s most profound and potentially practice-changing findings revolved around genetic testing. A remarkable 30% of women who tested positive for a genetic variant strongly linked to a higher breast cancer risk reported absolutely no family history of the disease. This discovery directly challenges current clinical guidelines, which often require a strong family history of breast or ovarian cancer as a prerequisite for genetic testing referral. Under existing protocols, many of these women with significant genetic predispositions would remain unidentified, delaying crucial interventions.
Beyond well-known pathogenic variants like BRCA1 and BRCA2, the WISDOM study also innovatively evaluated smaller DNA changes that can be aggregated into a polygenic risk score (PRS). A PRS represents an individual’s cumulative genetic predisposition to a disease, calculated by summing the effects of many common genetic variants, each contributing a small amount to overall risk. This sophisticated approach significantly improved the precision of individual risk predictions, leading to 12% to 14% of participants being reassigned to a different risk category based on this more granular genetic data.
"This is one of the first studies to offer genetic testing to all women, regardless of family history," highlighted co-author Allison S. Fiscalini, MPH, of UCSF, who serves as director of the Athena Breast Health Network and the WISDOM study. Fiscalini underscored the profound implications: "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention."
Broader Implications and Future Directions
The findings from the WISDOM study carry immense implications for public health policy, clinical practice, and patient empowerment. The shift from a universal age-based approach to a precision medicine model for breast cancer screening represents a significant evolution, promising more effective resource allocation and more personalized patient care.
Transforming Clinical Guidelines: Integrating these findings into national and international screening guidelines will be a complex but necessary undertaking. Major medical organizations will need to review the evidence, potentially revise their recommendations, and develop implementation strategies. This process often involves extensive deliberation, expert consensus, and pilot programs.
Implementation Challenges: The practical application of risk-based screening on a wide scale presents several challenges:
- Healthcare Infrastructure: Ensuring equitable access to comprehensive risk assessment tools, genetic counseling services, and advanced imaging modalities like MRI across all demographics and geographic regions will be critical.
- Physician Education: Healthcare providers, from primary care physicians to oncologists, will require extensive training on new risk models, genetic testing interpretation, and the nuances of personalized screening recommendations.
- Patient Education and Engagement: Communicating complex risk information effectively to the public, fostering understanding, and empowering women to participate in informed decision-making will be paramount.
- Cost-Effectiveness: While the study suggests long-term efficiency through optimized resource allocation, the initial investment in widespread genetic testing and advanced imaging for higher-risk groups will need careful economic evaluation and robust insurance coverage.
Policy Implications: The study’s revelations, particularly regarding genetic testing without family history, could drive changes in insurance coverage policies. Currently, many insurers only cover genetic testing for individuals meeting specific family history criteria. The WISDOM data provides a strong argument for broader coverage, recognizing that a significant portion of genetically high-risk individuals are currently missed.
Equity Considerations: As with any advanced medical intervention, ensuring equitable access to personalized screening across diverse populations, including racial and ethnic minorities and socioeconomically disadvantaged groups, will be a critical imperative. Disparities in breast cancer outcomes are well-documented, and new guidelines must actively work to reduce, not exacerbate, these inequalities.
WISDOM 2.0: The Next Frontier: Researchers are not resting on these laurels. The WISDOM 2.0 study is actively enrolling participants, continuing the vital work of refining risk assessment. The overarching goal is to enhance the ability to identify women at a higher likelihood of developing aggressive breast cancers, enabling the provision of screening and prevention strategies that are even more precisely tailored to their individual, long-term health needs. This continuous refinement underscores the dynamic nature of medical science and the ongoing commitment to improving patient outcomes.
The WISDOM study’s publication in JAMA and presentation at the San Antonio Breast Cancer Symposium mark a pivotal moment in breast cancer screening. It offers a compelling vision for a future where screening is not a blanket approach but a precisely tailored medical strategy, guided by individual biology and lifestyle, ultimately leading to safer, more effective, and more equitable breast health outcomes for all women.
The extensive collaborative effort behind this study involved numerous institutions and experts. Co-authors from UCSF included Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.
Additional investigators were affiliated with UC Los Angeles; UC Irvine; UC San Diego; San Francisco VA Health Care System; Sanford Health in North Dakota; University of Chicago; Diagnostic Center of Miami; University of Alabama; Virginia Commonwealth University; Weill Cornell Medicine in New York; and the Karolinska Institutet in Stockholm.
Study support was generously provided by the Patient Centered Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation, among other funding sources detailed in the full paper. Dr. Esserman disclosed her role as a medical advisory panel member for Blue Cross Blue Shield and receipt of author fees from the UpToDate electronic medical information resource. Conflicts of interest for other investigators are also detailed in the published paper.
